Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.57 |
| ▸ | MEN1 | O00255 | 4/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12946592 | 0.85 | SMN1; SMN2 (0.71) | LMNASMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL16864106 | 0.85 | LMNA (0.72) | LMNASMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL17535986 | 0.84 | LMNA (0.67) | LMNASMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL13757095 | 0.84 | LMNA (0.67) | LMNASMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL969926 | 0.84 | LMNA (0.67) | LMNASMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL4864670 | 0.83 | L3MBTL1 (0.77) | LMNASMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL6627628 | 0.82 | KDM4E (0.64) | LMNASMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL3718479 | 0.82 | KDM4E (0.64) | LMNASMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL12914957 | 0.82 | LMNA (0.64) | LMNASMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL8670380 | 0.81 | LMNA (0.63) | LMNASMN1; SMN2ALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872006-B2 | Pyrazole compounds having cannabinoid receptor (CB1) antagonizing activity | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-01-18 | — | — | US | disclosed |
| US-20090048256-A1 | Pyrazole Compounds Having Cannabinoid Receptor (CB1) Antagonizing Activity | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048256-A1 | Pyrazole Compounds Having Cannabinoid Receptor (CB1) Antagonizing Activity | CNR1, CNR2, OPRD1 | LMNA 4796/4885SMN1; SMN2 4351/4885ALDH1A1 1631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.